Treatment of anabolic-androgenic steroid dependence: Emerging evidence and its implications

Drug and Alcohol Dependence

Volumn 109, Issue 1-3, 2010, Pages 6-13

  Kanayama, Gen ^a,b   Brower, Kirk J ^c   Wood, Ruth I ^d   Hudson, James I ^a,b   Pope, Harrison G ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Anabolic androgenic steroids; Androgens; Men; Substance dependence; Testosterone; Treatment

Indexed keywords

ANABOLIC AGENT; ANDROGEN; ANTIDEPRESSANT AGENT; CHORIONIC GONADOTROPIN; CLOMIFENE; NALTREXONE;

ANABOLIC ANDROGENIC STEROID DEPENDENCE; BODY DYSMORPHIC DISORDER; BODY IMAGE; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DYSPHORIA; EVIDENCE BASED MEDICINE; HUMAN; HYPOGONADISM; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; INTERVENTION STUDY; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SUBSTANCE ABUSE; WITHDRAWAL SYNDROME;

ANABOLIC AGENTS; ANDROGENS; BODY IMAGE; GOALS; HUMANS; PATIENT ACCEPTANCE OF HEALTH CARE; STEROIDS; SUBSTANCE-RELATED DISORDERS;

ANIMALIA;

EID: 77953081344     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2010.01.011     Document Type: Review

References (152)

1. Alexander G.M., Packard M.G., Hines M. Testosterone has rewarding affective properties in male rats: implications for the biological basis of sexual motivation. Behav. Neurosci. 1994, 108:424-428.
2. Allen A., Hadley S.J., Kaplan A., Simeon D., Friedberg J., Priday L., Baker B.R., Greenberg J.L., Hollander E. An open-label trial of venlafaxine in body dysmorphic disorder. CNS Spectrosc. 2008, 13:138-144.
3. Allnutt S., Chaimowitz G. Anabolic steroid withdrawal depression: a case report. Can. J. Psychiatry 1994, 39:317-318.
4. Almeida O.P., Waterreus A., Spry N., Flicker L., Martins R.N. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology 2004, 29:1071-1081.
5. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1987, American Psychiatric Association, Washington, DC. 3rd rev. edition.
6. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) 1994, American Psychiatric Association, Washington, DC.
7. American Psychiatric Association Practice guideline for the treatment of patients with substance use disorders, second edition. Am. J. Psychiatry 2007, 164(Suppl. 4):75-123.
8. Arnedo M.T., Salvador A., Martinez-Sanchis S., Gonzalez-Bono E. Rewarding properties of testosterone in intact male mice: a pilot study. Pharmacol. Biochem. Behav. 2000, 65:327-332.
9. Arnedo M.T., Salvador A., Martinez-Sanchis S., Pellicer O. Similar rewarding effects of testosterone in mice rated as short and long attack latency individuals. Addict. Biol. 2002, 7:373-379.
10. Baker J.S., Graham M.R., Davies B. Steroid and prescription medicine abuse in the health and fitness community: a regional study. Eur. J. Intern. Med. 2006, 17:479-484.
11. Ballard C.L., Wood R.I. Intracerebroventricular self-administration of commonly abused anabolic-androgenic steroids in male hamsters (Mesocricetus auratus): nandrolone, drostanolone, oxymetholone, and stanozolol. Behav. Neurosci. 2005, 119:752-758.
12. Bickel W.K., Marsch L.A. Toward a behavioral economic understanding of drug dependence: delay discounting processes. Addiction 2001, 96:73-86.
13. Bing O., Heilig M., Kakoulidis P., Sundblad C., Wiklund L., Eriksson E. High doses of testosterone increase anticonflict behaviour in rat. Eur. Neuropsychopharmacol. 1998, 8:321-323.
14. Blouin A.G., Goldfield G.S. Body image and steroid use in male bodybuilders. Int. J. Eat. Disord. 1995, 18:159-165.
15. Boissy A., Bouissou M.F. Effects of androgen treatment on behavioral and physiological responses of heifers to fear-eliciting situations. Horm. Behav. 1994, 28:66-83.
16. Boyadjiev N.P., Georgieva K.N., Massaldjieva R.I., Gueorguiev S.I. Reversible hypogonadism and azoospermia as a result of anabolic-androgenic steroid use in a bodybuilder with personality disorder. a case report. J. Sports Med. Phys. Fitness 2000, 40:271-274.
17. Brower K.J. Rehabilitation for anabolic-androgenic steroid dependence. Clin. Sports Med. 1989, 1:171-181.
18. Brower K.J. Anabolic steroid abuse and dependence. Curr. Psychiatry Rep. 2002, 4:377-387.
19. Brower K.J. Anabolic steroid abuse and dependence in clinical practice. Physician Sports Med. 2009, 37:1-11.
20. Brower K.J., Blow F.C., Eliopulos G.A., Beresford T.P. Anabolic androgenic steroids and suicide. Am. J. Psychiatry 1989, 146:1075.
21. Brower K.J., Blow F.C., Hill E.M. Risk factors for anabolic-androgenic steroid use in men. J. Psychiatry Res. 1994, 28:369-380.
22. Cafri G., Thompson J.K., Ricciardelli L., McCabe M., Smolak L., Yesalis C. Pursuit of the muscular ideal: physical and psychological consequences and putative risk factors. Clin. Psychol. Rev. 2005, 25:215-239.
23. Carroll K.M., Ball S.A., Nich C., Martino S., Frankforter T.L., Farentinos C., Kunkel L.E., Mikulich-Gilbertson S.K., Morgenstern J., Obert J.L., Polcin D., Snead N., Woody G.E. Motivational interviewing to improve treatment engagement and outcome in individuals seeking treatment for substance abuse: a multisite effectiveness study. Drug Alcohol Depend. 2006, 81:301-312.
24. Carroll K.M., Onken L.S. Behavioral therapies for drug abuse. Am. J. Psychiatry 2005, 162:1452-1460.
25. Carroll K.M., Rounsaville B.J. A perfect platform: combining contingency management with medications for drug abuse. Am. J. Drug Alcohol Abuse 2007, 33:343-365.
26. Choi P.Y., Pope H.G. Violence toward women and illicit androgenic-anabolic steroid use. Ann. Clin. Psychiatry 1994, 6:21-25.
27. Cohen J., Collins R., Darkes J., Gwartney D. A league of their own: demographics, motivations and patterns of use of 1,955 male adult non-medical anabolic steroid users in the United States. J. Int. Soc. Sports Nutr. 2007, 4:12.
28. Cole J.C., Smith R., Halford J.C., Wagstaff G.F. A preliminary investigation into the relationship between anabolic-androgenic steroid use and the symptoms of reverse anorexia in both current and ex-users. Psychopharmacology (Berl.) 2003, 166:424-429.
29. Collins R. Legal Muscle: Anabolics in America 2002, Legal Muscle Publishing, East Meadow, NY.
30. Corcoran J.P., Longo E.D. Psychological treatment of anabolic-androgenic steroid-dependent individuals. J. Subst. Abuse Treat. 1992, 9:229-235.
31. D'Andrea A., Caso P., Salerno G., Scarafile R., De Corato G., Mita C., Di Salvo G., Severino S., Cuomo S., Liccardo B., Esposito N., Calabro R. Left ventricular early myocardial dysfunction after chronic misuse of anabolic androgenic steroids: a Doppler myocardial and strain imaging analysis. Br. J. Sports Med. 2007, 41:149-155.
32. de Beun R., Jansen E., Slangen J.L., Van de Poll N.E. Testosterone as appetitive and discriminative stimulus in rats: sex- and dose-dependent effects. Physiol. Behav. 1992, 52:629-634.
33. de Wit H. Impulsivity as a determinant and consequence of drug use: a review of underlying processes. Addict. Biol. 2009, 14:22-31.
34. Dodge T., Litt D., Seitchik A., Bennett S. Drive for muscularity and beliefs about legal performance enhancing substances as predictors of current use and willingness to use. J. Health Psychol. 2008, 13:1173-1179.
35. Dom G., Sabbe B., Hulstijn W., van den Brink W. Substance use disorders and the orbitofrontal cortex: systematic review of behavioural decision-making and neuroimaging studies. Br. J. Psychiatry 2005, 187:209-220.
36. Frye C.A. Some rewarding effects of androgens may be mediated by actions of its 5alpha-reduced metabolite 3alpha-androstanediol. Pharmacol. Biochem. Behav. 2007, 86:354-367.
37. Galduroz J.C., Noto A.R., Nappo S.A., Carlini E.A. Household survey on drug abuse in Brazil: study involving the 107 major cities of the country-2001. Addict. Behav. 2005, 30:545-556.
38. Gazvani M.R., Buckett W., Luckas M.J., Aird I.A., Hipkin L.J., Lewis-Jones D.I. Conservative management of azoospermia following steroid abuse. Hum. Reprod. 1997, 12:1706-1708.
39. Gottesman I.I., Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 2003, 160:636-645.
40. Gray P.B., Yang C.F., Pope H.G. Fathers have lower salivary testosterone levels than unmarried men and married non-fathers in Beijing. China Proc. Biol. Sci. 2006, 273:333-339.
41. Guay A.T., Jacobson J., Perez J.B., Hodge M.B., Velasquez E. Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit?. Int. J. Impot. Res. 2003, 15:156-165.
42. Hall R.C., Hall R.C. Abuse of supraphysiologic doses of anabolic steroids. South. Med. J. 2005, 98:550-555.
43. Hall R.C., Hall R.C., Chapman M.J. Psychiatric complications of anabolic steroid abuse. Psychosomatics 2005, 46:285-290.
44. Handelsman D.J., Gupta L. Prevalence and risk factors for anabolic-androgenic steroid abuse in Australian high school students. Int. J. Androl. 1997, 20:159-164.
45. Hartgens F., Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004, 34:513-554.
46. Herlitz L.C., Markowitz G.S., Farris A.B., Schwimmer J.A., Stokes M.B., Kunis C., Colvin R.B., D'Agati V.D. Development of focal segmental glomerulosclerosis after anabolic steroid abuse. J. Am. Soc. Nephrol. 2009.
47. Hermans E.J., Putman P., Baas J.M., Gecks N.M., Kenemans J.L., van Honk J. Exogenous testosterone attenuates the integrated central stress response in healthy young women. Psychoneuroendocrinology 2007, 32:1052-1061.
48. Hildebrandt T., Langenbucher J.W., Carr S.J., Sanjuan P. Modeling population heterogeneity in appearance- and performance-enhancing drug (APED) use: applications of mixture modeling in 400 regular APED users. J. Abnorm. Psychol. 2007, 116:717-733.
49. Hildebrandt T., Schlundt D., Langenbucher J., Chung T. Presence of muscle dysmorphia symptomology among male weightlifters. Compr. Psychiatry 2006, 47:127-135.
50. Hochberg Z., Pacak K., Chrousos G.P. Endocrine withdrawal syndromes. Endocr. Rev. 2003, 24:523-538.
51. Hollander E., Allen A., Kwon J., Aronowitz B., Schmeidler J., Wong C., Simeon D. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch. Gen. Psychiatry 1999, 56:1033-1039.
52. Holt R.I., Sonksen P.H. Growth hormone IGF-I and insulin and their abuse in sport. Br. J. Pharmacol. 2008, 154:542-556.
53. Ipser J.C., Sander C., Stein D.J. Pharmacotherapy and psychotherapy for body dysmorphic disorder. Cochrane Database Syst. Rev. 2009, CD005332.
54. Jarow J.P., Lipshultz L.I. Anabolic steroid-induced hypogonadotropic hypogonadism. Am. J. Sports Med. 1990, 18:429-431.
55. Johansson P., Lindqvist A., Nyberg F., Fahlke C. Anabolic androgenic steroids affects alcohol intake, defensive behaviors and brain opioid peptides in the rat. Pharmacol. Biochem. Behav. 2000, 67:271-279.
56. Johnson L.R., Wood R.I. Oral testosterone self-administration in male hamsters. Neuroendocrinology 2001, 73:285-292.
57. Johnson L.D., O'Malley P.M., Bachman J.G., Schulenberg J.E., Johnson L.D., O'Malley P.M. Monitoring the Future National Survey Results on Drug Use, 1975-2008. Vol. II: College Students and Adults Ages 19-50 2009, National Institute on Drug Abuse, Bethesda, MD, (NIH Publication No. 09-7402).
58. Kalivas P.W., Volkow N.D. The neural basis of addiction: a pathology of motivation and choice. Am. J. Psychiatry 2005, 162:1403-1413.
59. Kanayama G., Amiaz R., Seidman S., Pope H.G. Testosterone supplementation for depressed men: current research and suggested treatment guidelines. Exp. Clin. Psychopharmacol. 2007, 15:529-538.
60. Kanayama G., Barry S., Hudson J.I., Pope H.G. Body image and attitudes toward male roles in anabolic-androgenic steroid users. Am. J. Psychiatry 2006, 163:697-703.
61. Kanayama G., Boynes M., Hudson J.I., Field A.E., Pope H.G. Anabolic steroid abuse among teenage girls: an illusory problem?. Drug Alcohol Depend. 2007, 88:156-162. (PMC 1978191).
62. Kanayama G., Brower K.J., Wood R.I., Hudson J.I., Pope H.G. Anabolic-androgenic steroid dependence: an emerging disorder. Addiction 2009, 104:1966-1978.
63. Kanayama G., Brower K.J., Wood R.I., Hudson J.I., Pope H.G. Issues for DSM-V: clarifying the diagnostic criteria for anabolic-androgenic steroid dependence. Am. J. Psychiatry 2009, 166:642-645.
64. Kanayama G., Cohane G.H., Weiss R.D., Pope H.G. Past anabolic-androgenic steroid use among men admitted for substance abuse treatment: an underrecognized problem?. J. Clin. Psychiatry 2003, 64:156-160.
65. Kanayama, G., Hudson, J.I., Pope, H.G., in press. Illicit anabolic-androgenic steroid use. Horm. Behav.
66. Kanayama G., Hudson J.I., Pope H.G. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern?. Drug Alcohol Depend. 2008, 98:1-12.
67. Kanayama G., Hudson J.I., Pope H.G. Features of men with anabolic-androgenic steroid dependence: a comparison with nondependent AAS users and with AAS nonusers. Drug Alcohol Depend. 2009, 102:130-137.
68. Kanayama G., Pope H.G., Cohane G., Hudson J.I. Risk factors for anabolic-androgenic steroid use among weightlifters: a case-control study. Drug Alcohol Depend. 2003, 71:77-86.
69. Kashkin K.B., Kleber H.D. Hooked on hormones? An anabolic steroid addiction hypothesis. JAMA 1989, 262:3166-3170.
70. Kasikcioglu E., Oflaz H., Umman B., Bugra Z. Androgenic anabolic steroids also impair right ventricular function. Int. J. Cardiol. 2009, 134:123-125.
71. Kilmer J., Cronce J., Palmer R. Relapse prevention for abuse of club drugs, hallucinogens, inhalants, and steroids. Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors 2005, Guilford Press, New York. 2nd edition. G. Marlatt, D. Donovan (Eds.).
72. Kindlundh A.M., Hagekull B., Isacson D.G., Nyberg F. Adolescent use of anabolic-androgenic steroids and relations to self-reports of social, personality and health aspects. Eur. J. Public Health 2001, 11:322-328.
73. Knuth U.A., Maniera H., Nieschlag E. Anabolic steroids and semen parameters in bodybuilders. Fertil. Steril. 1989, 52:1041-1047.
74. Kokkevi A., Fotiou A., Chileva A., Nociar A., Miller P. Daily exercise and anabolic steroids use in adolescents: a cross-national European study. Subst. Use Misuse 2008, 43:2053-2065.
75. Kouri E.M., Pope H.G., Katz D.L., Oliva P. Fat-free mass index in users and nonusers of anabolic-androgenic steroids. Clin. J. Sport Med. 1995, 5:223-228.
76. Krieg A., Scharhag J., Albers T., Kindermann W., Urhausen A. Cardiac tissue Doppler in steroid users. Int. J. Sports Med. 2007, 28:638-643.
77. Kurling S., Kankaanpaa A., Seppala T. Sub-chronic nandrolone treatment modifies neurochemical and behavioral effects of amphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in rats. Behav Brain Res. 2008, 189:191-201.
78. Li J., Al-Azzawi F. Mechanism of androgen receptor action. Maturitas 2009, 63:142-148.
79. Lindqvist A.S., Johansson-Steensland P., Nyberg F., Fahlke C. Anabolic androgenic steroid affects competitive behaviour, behavioural response to ethanol and brain serotonin levels. Behav. Brain Res. 2002, 133:21-29.
80. Litt D., Dodge T. A longitudinal investigation of the drive for muscularity scale: predicting use of performance enhancing substances and weightlifting among males. Body Image 2008, 5:346-351.
81. Liu P.Y., Death A.K., Handelsman D.J. Androgens and cardiovascular disease. Endocr. Rev. 2003, 24:313-340.
82. Llewellyn W. Anabolics 2009, Molecular Nutrition, Jupiter, FL. 9th edition.
83. Malone D.A., Dimeff R.J. The use of fluoxetine in depression associated with anabolic steroid withdrawal: a case series. J. Clin. Psychiatry 1992, 53:130-132.
84. Malone D.A., Dimeff R.J., Lombardo J.A., Sample R.H. Psychiatric effects and psychoactive substance use in anabolic-androgenic steroid users. Clin. J. Sport Med. 1995, 5:25-31.
85. Mannelli P., Peindl K., Masand P.S., Patkar A.A. Long-acting injectable naltrexone for the treatment of alcohol dependence. Expert. Rev. Neurother. 2007, 7:1265-1277.
86. Maravelias C., Dona A., Stefanidou M., Spiliopoulou C. Adverse effects of anabolic steroids in athletes. A constant threat. Toxicol. Lett. 2005, 158:167-175.
87. McBride A.J., Williamson K., Petersen T. Three cases of nalbuphine hydrochloride dependence associated with anabolic steroid use. Br. J. Sports Med. 1996, 30:69-70.
88. McKay D. Two-year follow-up of behavioral treatment and maintenance for body dysmorphic disorder. Behav. Modif. 1999, 23:620-629.
89. McKay D., Todaro J., Neziroglu F., Campisi T., Moritz E.K., Yaryura-Tobias J.A. Body dysmorphic disorder: a preliminary evaluation of treatment and maintenance using exposure with response prevention. Behav. Res. Ther. 1997, 35:67-70.
90. Medras M., Tworowska U. Treatment strategies of withdrawal from long-term use of anabolic-androgenic steroids. Pol. Merkur. Lekarski. 2001, 11:535-538.
91. Menon D.K. Successful treatment of anabolic steroid-induced azoospermia with human chorionic gonadotropin and human menopausal gonadotropin. Fertil. Steril. 2003, 79(Suppl. 3):1659-1661.
92. Miller W.R., Rollnick S. Motivational Interviewing: Preparing People for Change 2002, Guilford Press, New York. 2nd edition.
93. Nilsson S., Baigi A., Marklund B., Fridlund B. The prevalence of the use of androgenic anabolic steroids by adolescents in a county of Sweden. Eur. J. Public Health 2001, 11:195-197.
94. O'Malley S.S., Garbutt J.C., Gastfriend D.R., Dong Q., Kranzler H.R. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J. Clin. Psychopharmacol. 2007, 27:507-512.
95. Olivardia R., Pope H.G., Hudson J.I. Muscle dysmorphia in male weightlifters: a case-control study. Am. J. Psychiatry 2000, 157:1291-1296.
96. Packard M.G., Cornell A.H., Alexander G.M. Rewarding affective properties of intra-nucleus accumbens injections of testosterone. Behav. Neurosci. 1997, 111:219-224.
97. Papazisis G., Kouvelas D., Mastrogianni A., Karastergiou A. Anabolic androgenic steroid abuse and mood disorder: a case report. Int. J. Neuropsychopharmacol. 2007, 10:291-293.
98. Perry P.J., Kutscher E.C., Lund B.C., Yates W.R., Holman T.L., Demers L. Measures of aggression and mood changes in male weightlifters with and without androgenic anabolic steroid use. J. Forensic Sci. 2003, 48:646-651.
99. Peters K.D., Wood R.I. Androgen dependence in hamsters: overdose, tolerance, and potential opioidergic mechanisms. Neuroscience 2005, 130:971-981.
100. Petersson A., Garle M., Holmgren P., Druid H., Krantz P., Thiblin I. Toxicological findings and manner of death in autopsied users of anabolic androgenic steroids. Drug Alcohol Depend. 2006, 81:241-249.
101. Phillips K.A. An open-label study of escitalopram in body dysmorphic disorder. Int. Clin. Psychopharmacol. 2006, 21:177-179.
102. Phillips K.A., Albertini R.S., Rasmussen S.A. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch. Gen. Psychiatry 2002, 59:381-388.
103. Phillips K.A., Najjar F. An open-label study of citalopram in body dysmorphic disorder. J. Clin. Psychiatry 2003, 64:715-720.
104. Phillips K.A., Rasmussen S.A. Change in psychosocial functioning and quality of life of patients with body dysmorphic disorder treated with fluoxetine: a placebo-controlled study. Psychosomatics 2004, 45:438-444.
105. Pope H., Phillips K., Olivardia R. The Adonis Complex: The Secret Crisis of Male Body Obsession 2000, Simon & Schuster, New York.
106. Pope H.G., Brower K.J. Treatment of anabolic-androgenic steroid-related disorders. The American Psychiatric Publishing Textbook of Substance Abuse Treatment 2008, 237-246. American Psychiatric Publishing, Washington, DC. 4th edition. M. Galanter, H. Kleber (Eds.).
107. Pope H.G., Brower K.J. Anabolic-Androgenic Steroid-Related Disorders. Comprehensive Textbook of Psychiatry 2009, 1419-1431. Lippincott Williams & Wilkins, Philadelphia, PA. 9th edition. B. Sadock, V. Sadock (Eds.).
108. Pope H.G., Gruber A.J., Choi P., Olivardia R., Phillips K.A. Muscle dysmorphia. An underrecognized form of body dysmorphic disorder. Psychosomatics 1997, 38:548-557.
109. Pope H.G., Gruber A.J., Mangweth B., Bureau B., deCol C., Jouvent R., Hudson J.I. Body image perception among men in three countries. Am. J. Psychiatry 2000, 157:1297-1301.
110. Pope H.G., Katz D.L. Affective and psychotic symptoms associated with anabolic steroid use. Am. J. Psychiatry 1988, 145:487-490.
111. Pope H.G., Katz D.L., Hudson J.I. Anorexia nervosa and " reverse anorexia" among 108 male bodybuilders. Compr. Psychiatry 1993, 34:406-409.
112. Pope H.G., Kouri E.M., Hudson J.I. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Arch. Gen. Psychiatry 2000, 57:133-140. (discussion 155-136).
113. Pope H.G., Olivardia R., Borowiecki J.J., Cohane G.H. The growing commercial value of the male body: a longitudinal survey of advertising in women's magazines. Psychother. Psychosom. 2001, 70:189-192.
114. Pope H.G., Olivardia R., Gruber A., Borowiecki J. Evolving ideals of male body image as seen through action toys. Int. J. Eat. Disord. 1999, 26:65-72.
115. Pope H.G., Kanayama G., Ionescu-Pioggia M., Hudson J.I. Anabolic steroid users' attitudes towards physicians. Addiction 2004, 99:1189-1194.
116. Pope H.G., Katz D.L. Psychiatric effects of exogenous anabolic-androgenic steroids. Psychoneuroendocrinology: The Scientific Basis of Clinical Practice 2003, 331-358. American Psychiatric Press, Washington, DC. O.M. Wolkowitz, A.J. Rothschild (Eds.).
117. Porcerelli J.H., Sandler B.A. Narcissism and empathy in steroid users. Am. J. Psychiatry 1995, 152:1672-1674.
118. Repcekova D., Mikulaj L. Plasma testosterone response to HCG in normal men without and after administration of anabolic drug. Endokrinologie 1977, 69:115-118.
119. Reyes-Fuentes A., Veldhuis J.D. Neuroendocrine physiology of the normal male gonadal axis. Endocrinol. Metab. Clin. North Am. 1993, 22:93-124.
120. Reynolds B. A review of delay-discounting research with humans: relations to drug use and gambling. Behav. Pharmacol. 2006, 17:651-667.
121. Rosen J.C., Reiter J., Orosan P. Cognitive-behavioral body image therapy for body dysmorphic disorder. J. Consult. Clin. Psychol. 1995, 63:263-269.
122. Santen R.J. Feedback control of luteinizing hormone and follicle-stimulating hormone secretion by testosterone and estradiol in men: physiological and clinical implications. Clin. Biochem. 1981, 14:243-251.
123. Schmidt P.J., Berlin K.L., Danaceau M.A., Neeren A., Haq N.A., Roca C.A., Rubinow D.R. The effects of pharmacologically induced hypogonadism on mood in healthy men. Arch. Gen. Psychiatry 2004, 61:997-1004.
124. Skarberg K., Nyberg F., Engstrom I. Multisubstance use as a feature of addiction to anabolic-androgenic steroids. Eur. Addict. Res. 2009, 15:99-106.
125. Stitzer M.L., Vandrey R. Contingency management: utility in the treatment of drug abuse disorders. Clin. Pharmacol. Ther. 2008, 83:644-647.
126. Substance Abuse and Mental Health Services Administration (SAMHSA), 1994. National Survey on Drug Use and Health (formerly called the National Household Survey). United States Department of Health and Human Services. Available online at: ; data for 1994-B survey available online at: http://www.icpsr.umich.edu/cgi-bin/SDA/SAMHDA/hsda?samhda+nhsda94b.
127. Swerdloff R.S., Wang C., Hikim A.P.S. Hypothalamic-pituitary-gonadal axis in men. Hormones, Brain and Behavior 2002, 1-36. Elsevier, San Diego. D. Pfaff, A. Arnold, A. Etgen, S. Fahrbach, R. Rubin (Eds.).
128. Tan R.S., Carrejo M.H., Chen D. An unusual case of vascular hypogonadism treated with clomiphene citrate and testosterone replacement. Andrologia 2009, 41:63-65.
129. Tan R.S., Scally M.C. Anabolic steroid-induced hypogonadism-towards a unified hypothesis of anabolic steroid action. Med. Hypotheses 2009, 72:723-728.
130. Tan R.S., Vasudevan D. Use of clomiphene citrate to reverse premature andropause secondary to steroid abuse. Fertil. Steril. 2003, 79:203-205.
131. Tennant F., Black D.L., Voy R.O. Anabolic steroid dependence with opioid-type features. N. Engl. J. Med. 1988, 319:578.
132. Thiblin I., Lindquist O., Rajs J. Cause and manner of death among users of anabolic androgenic steroids. J. Forensic Sci. 2000, 45:16-23.
133. Thiblin I., Runeson B., Rajs J. Anabolic androgenic steroids and suicide. Ann. Clin. Psychiatry 1999, 11:223-231.
134. Trenton A.J., Currier G.W. Behavioural manifestations of anabolic steroid use. CNS Drugs 2005, 19:571-595.
135. Turek P.J., Williams R.H., Gilbaugh J.H., Lipshultz L.I. The reversibility of anabolic steroid-induced azoospermia. J. Urol. 1995, 153:1628-1630.
136. Urhausen A., Torsten A., Wilfried K. Reversibility of the effects on blood cells, lipids, liver function and hormones in former anabolic-androgenic steroid abusers. J. Steroid Biochem. Mol. Biol 2003, 84:369-375.
137. van Breda E., Keizer H.A., Kuipers H., Wolffenbuttel B.H. Androgenic anabolic steroid use and severe hypothalamic-pituitary dysfunction: a case study. Int. J. Sports Med. 2003, 24:195-196.
138. van Honk J., Schutter D.J., Hermans E.J., Putman P., Tuiten A., Koppeschaar H. Testosterone shifts the balance between sensitivity for punishment and reward in healthy young women. Psychoneuroendocrinology 2004, 29:937-943.
139. Veale D., Gournay K., Dryden W., Boocock A., Shah F., Willson R., Walburn J. Body dysmorphic disorder: a cognitive behavioural model and pilot randomised controlled trial. Behav. Res. Ther. 1996, 34:717-729.
140. Verdejo-Garcia A., Bechara A. A somatic marker theory of addiction. Neuropharmacology 2009, 56(Suppl. 1):48-62.
141. Verdejo-Garcia A., Lawrence A.J., Clark L. Impulsivity as a vulnerability marker for substance-use disorders: review of findings from high-risk research, problem gamblers and genetic association studies. Neurosci. Biobehav. Rev. 2008, 32:777-810.
142. Wade N. Anabolic steroids: doctors denounce them, but athletes aren't listening. Science 1972, 176:1399-1403.
143. Weiner R.B., Kanayama G., Hudson J.I., Hutter A.M., Picard M.H., Pope H.G., Baggish A.L. Chronic anabolic-androgenic steroid use is associated with left ventricular systolic and diastolic dysfunction. Circulation 2009, 120:S741. (Abstract 3048).
144. Wines J.D., Gruber A.J., Pope H.G., Lukas S.E. Nalbuphine hydrochloride dependence in anabolic steroid users. Am. J. Addict. 1999, 8:161-164.
145. Winters S.J., Janick J.J., Loriaux D.L., Sherins R.J. Studies on the role of sex steroids in the feedback control of gonadotropin concentrations in men. II. Use of the estrogen antagonist, clomiphene citrate. J. Clin. Endocrinol. Metab. 1979, 48:222-227.
146. Winters S.J., Troen P. Evidence for a role of endogenous estrogen in the hypothalamic control of gonadotropin secretion in men. J. Clin. Endocrinol. Metab. 1985, 61:842-845.
147. Wood R.I. Anabolic-androgenic steroid dependence? Insights from animals and humans. Front Neuroendocrinol. 2008, 29:490-506. PMC 2585375.
148. Wood R.I., Johnson L.R., Chu L., Schad C., Self D.W. Testosterone reinforcement: intravenous and intracerebroventricular self-administration in male rats and hamsters. Psychopharmacology (Berl.) 2004, 171:298-305.
149. Woody G.E. Research findings on psychotherapy of addictive disorders. Am. J. Addict. 2003, 12(Suppl. 2):S19-S26.
150. Woody G.E., McLellan A.T., Luborsky L., O'Brien C.P. Sociopathy and psychotherapy outcome. Arch. Gen. Psychiatry 1985, 42:1081-1086.
151. Yang C.F., Gray P., Pope H.G. Male body image in Taiwan versus the West: Yanggang Zhiqi meets the Adonis complex. Am. J. Psychiatry 2005, 162:263-269.
152. Yates W.R., Perry P.J., Andersen K.H. Illicit anabolic steroid use: a controlled personality study. Acta Psychiatry Scand. 1990, 81:548-550.